Insights
Insights From Our Experts
Articles
Delivering Value to Leading Payers
Assessment of Strategic Priorities, Competitive Dynamics, and Innovations Impacting Biopharma Access Seven leading payers represent nearly half of all US medical lives and 54% of pharmacy lives: UnitedHealth Group CVS Health, Cigna Elevance Health Kaiser Permanente…
APACMed Digital Health Reimbursement Policy Forum
Introduction The APACMed Policy Forum on Digital Health Reimbursement was held on 23 May 2023, with participants from Australia, Japan, Singapore, South Korea, Germany, France, and the UK. Several digital health policymakers, academicians, and experts from…
Considerations for Globalization of Medical Information Services: A Service Partner Perspective
Posted by
Carolyn Quon, PharmD , Michael DeLuca , Lindsey Buyskes, B Pharm , Varun Pandey, PhD on September 27, 20239/27/23
This poster details the considerations for globalizing medical information (MI) services. Traditionally, pharmaceutical companies began in one geographical region before expanding, but evolving regulations and research priorities for rare diseases, oncology/hematology, immunology, and cell and gene…
New Models of Benefits Verification Solve for Complexity, Accelerate Speed to Therapy and Deliver Price Transparency
Navigating health care insurance coverage can be a supremely convoluted process for anyone, especially patients or caregivers recently faced with coping with a life-threatening disease. While the advancement of many new treatments and scientific innovations in…
Orchestrating Experiences That Simultaneously Drive Brand Impact and Customer Delight
The evolving landscape of HCP and patient engagement in the pharmaceutical industry necessitates omnichannel solutions that successfully cover multiple touchpoints such as field, web, email, conferences and more. Not only are brands expected to cover these…
Balancing the Portfolio: How Extending Mature Brands’ Success Can Replenish Costs Invested In Launching New Products
The traditional mindset toward established brands in the pharmaceutical industry has largely been to let focus fade from them and shift entirely to developing and launching new products. With emphasis placed almost exclusively on new product…
Asset Optimization: Breathe New Life Into Mature Brands with EVERSANA REIGNITE™
Maximizing revenue potential throughout products’ entire lifecycles before they reach loss of exclusivity (LOE) is the most impactful return on investment manufacturers can make for their established brands. While many companies figuratively put their mature brands…
Continuous Manufacturing of Pharmaceutical Products: The New Norm
The life sciences sector is changing for the new pharma generation with the introduction of many forms of updated technology and solutions. Continuous manufacturing (CM) is a perfect example. CM is a method for manufacturing pharmaceutical…
Unlocking Your Full North American Potential: Coordinating Launches in The U.S. and Canada
Posted by
Adam Hardy , Charles Pirraglia , Deborah Brown , Kerem Can Alp , Ryan H. Brown on September 6, 20239/6/23
Discover the groundbreaking strategy that could redefine pharmaceutical launches and propel your product’s success across North America. In the realm of pharmaceutical launches, a paradigm shift is underway, challenging the conventional sequential approach and calling for…
Unlocking Global Success: The Crucial Role of Integrated HEOR Programs in New Product Launches
Posted on August 25, 20238/25/23
Author: Kirk Szafranski, Director, HEOR, Value & Evidence Health Economics and Outcomes Research (HEOR) programs play a pivotal role in assessing a product’s value, cost-effectiveness, and real-world impact on patient outcomes, which are critical factors influencing…